Patient self-administration via subcutaneous injection
Share this resource with your patients to help them feel confident when administering MENOPUR
The broadest insurance coverage of any gonadotropin1
With the growing availability of break employer-sponsored fertility benefits, it’s worth noting that medical and pharmacy coverage are often handled separately.
69% of US employers provide fertility coverage1*
80% of those with fertility benefits have separate drug and medical plans2
MENOPUR is covered
by 90% of commercial
benefits packages1
Coverage as of 6/25. Please note: Subject to change based on individual plan coverage. Check the member’s benefits for more details.*Results from a 2021 survey of 459 employer groups with ≥ 500 employees.
Covered on many of the
largest health care plans†,
including:
- CVS Caremark
- Optum
- United Healthcare (UHC)
- HCSC‡
- Express Scripts
- And many Blue Cross Blue Shield plans
†Coverage as of 1/25. Please note: Subject to change based on individual plan coverage. Check the member’s benefits for more details.
‡HCSC includes several Blue Cross Blue Shields plans in the following states; Illinois, Montana, New Mexico, Oklahoma, and Texas.
Support that moves you and your patients forward
A dedicated platform for individuals and couples at every stage of their fertility journey
- Educational content
- Tips for navigating insurance
- Support on the path to success with tools and resources
IMPORTANT SAFETY INFORMATION
- MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.
- MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.
- The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.
INDICATION FOR USE
- MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program.
You are encouraged to report negative side effects of prescription drugs to FDA.
Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.
Please see full Prescribing Information.
Please see Important Safety Information and Full Prescribing Information